Clinical Trial Update: A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease [Phase 3]

View source ↗

Summary

Sanofi's Phase 3 trial is evaluating rilzabrutinib versus placebo for immunoglobulin G4-related disease, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Sanofi | Conditions: Immunoglobulin G4 Related Disease | Phase 3 | Status: RECRUITING